
    
      This was a prospective, randomized, double-blind, double-dummy, balanced, placebo and
      active-controlled, six-way crossover Phase 1 study with six single-dose treatment sessions.
      The profile of acute effects on pharmacodynamic abuse potential measures of different
      almorexant doses was compared with that of placebo and two doses of zolpidem.
    
  